首页|No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy

No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Objective:To assess the risk of aristolochic acid(AA)-associated cancer in patients with AA nephropathy(AAN).Methods:A retrospective study was conducted on patients diagnosed with AAN at Peking University First Hospital from January 1997 to December 2014.Long-term surveillance and follow-up data were analyzed to investigate the influence of different factors on the prevalence of cancer.The primary endpoint was the incidence of liver cancer,and the secondary endpoint was the incidence of urinary cancer during 1 year after taking AA-containing medication to 2014.Results:A total of 337 patients diagnosed with AAN were included in this study.From the initiation of taking AA to the termination of follow-up,39 patients were diagnosed with cancer.No cases of liver cancer were observed throughout the entire follow-up period,with urinary cancer being the predominant type(34/39,87.17％).Logistic regression analysis showed that age,follow-up period,and diabetes were potential risk factors,however,the dosage of the drug was not significantly associated with urinary cancer.Conclusions:No cases of liver cancer were observed at the end of follow-up.However,a high prevalence of urinary cancer was observed in AAN patients.Establishing a direct causality between AA and HCC is challenging.

aristolochic acidhepatocellular carcinomaurinary cancerdrug safetyretrospective study

SU Tao、FANG Zhi-e、GUO Yu-ming、WANG Chun-yu、WANG Jia-bo、JI Dong、BAI Zhao-fang、YANG Li、XIAO Xiao-he

展开 >

Renal Division,Department of Medicine,Peking University First Hospital,Beijing(100034),China

Department of Pharmacy,Chongqing Hospital of Traditional Chinese Medicine,Chongqing(400021),China

Department of Hepatology,Fifth Medical Center of Chinese PLA General Hospital,Beijing(100039),China

China Military Institute of Chinese Materia,Fifth Medical Center of Chinese PLA General Hospital,Beijing(100039),China

Phase I Clinical Trials Unit,Department of Medicine for Infectious Diseases,Fifth Medical Center of Chinese PLA General Hospital,Beijing(100039),China

Department of Pharmacy,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan(250000),China

National Key Laboratory of Kidney Diseases,Beijing(100039),China

展开 >

National Key Technology R&D ProgramInnovation Team and Talents Cultivation Program of National Administration of Traditional Chinese MedicineScience and Technology Project Affiliated to the Education Department of Chongqing Municipality

2018ZX09101002-001-002ZYYCXTD-C-202005KJQN202215119

2024

10.1007/s11655-023-3560-0

中国结合医学杂志(英文版)
中国中西医结合学会 中国中医研究院

中国结合医学杂志(英文版)

CSTPCD
影响因子：1.056
ISSN：1672-0415
年,卷(期)：2024.30(2)
  • 27